Company Overview and News
Investors will hope shares in mixer maker Fevertree Drinks will regain their fizz as it begins to step up its overseas expansion. The Aim-listed firm’s share price has surged 101pc in the last year but the market darling’s momentum was slowed in May when it failed to deliver its customary earnings upgrade. City analysts warned that investors may have to brace for a transition year as it tries to tap the huge US market to maintain its explosive growth.
KAZ RDS.B RDS.A AAL BATS RDSB 4162 RDSA JMPLF FQVTF FEVR AAUKF RYDBF JMPLY RYDAF NGLOY
I like the company's offered 10% discount on stock dividends - this allows shareholders to quickly expand their positions at a very advantageous price.
HD RIO RIO RDSB OCI RDSA KGFHY WRDEF RTPPF BINCY RTNTF OCINF MBSRF RYDAF BPOSY BQNBF RDS.B C RDS.A MBSRY RBSFY CTTAF OCIP BPOSF RIO CTTAY RYDBF
Earnings are expected from a third of S&P 500 companies in the week ahead, and there will also be an important report card on the economy, with second-quarter GDP expected to be the strongest in four years.
LMT DB TXN XOM UAA HA RDSB RDSA MPC NOC BSX GM.WS.A GM.WS.B JNPR GM.WS.C GM RYDAF FSLR CIT EA RDS.B RDS.A GILD VLO UTX SYF NSC CMG UA AVY TSCO FFIV VIRT RYDBF LVS GM.WSB
WASHINGTON (Reuters) - Baltimore filed a lawsuit on Friday against 26 oil and gas companies and entities, including BP Plc, Chevron Corp and Exxon Mobil Corp, for knowingly contributing to what the city called the catastrophic consequences of climate change.
RDS.B RDS.A CNX.WI HES XOM BP RDSB RDSA BP.A BP.B HES.PRA CEIX.WI BP CVX RYDBF MRO BPAQF RYDAF CEIX CNX
Cheniere Energy Partners LP (CQP) is a Delaware-based subsidiary of Cheniere Energy Inc. (NYSEMKT:LNG) and is engaged in the development, construction, and operation of liquefaction facilities adjacent to the Sabine Pass LNG Terminal. Its operations are based in Louisiana where it operates the Sabine Pass LNG receiving terminal and Creole Trail Pipeline through its wholly owned subsidiaries.
CQP RDS.B RDS.A LNG RYDBF RDSB RDSA RYDAF
LONDON (Bloomberg) -- Royal Dutch Shell Plc is in talks to sell two Nigerian oil licenses in an area that’s at the heart of environmental and human rights controversies for $2 billion, according to people familiar with the plan.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF
SAN RAMON, Calif.--(BUSINESS WIRE)--Jul. 19, 2018-- The U.S. District Court for the Southern District of New York today granted Chevron Corporation's Motion to Dismiss the climate change lawsuit filed against it by the City of New York. This decision follows the June 25th order by the U.S. District Court for the Northern District of California, which dismissed substantively identical complaints that the same plaintiffs' lawyers had filed against Chevron on behalf of the cities of San Francisco and Oakland.
RDS.B RDS.A CVX RYDBF RDSB RDSA RYDAF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET